|
Market Closed -
NYSE
04:00:02 2026-09-01 pm EDT
|
5-day change | 1st Jan Change | ||
| 403.04 USD | +2.67% |
|
+1.05% | +14.97% |
| Aug. 25 | HHS Plans 2 New FDA Deputy Commissioner Roles Covering Drugs, Technology | MT |
| Aug. 25 | HHS Plans 2 New FDA Deputy Commissioner Roles Covering Drugs, Technology, CNBC Reports | MT |
| Market Cap | 87.41B 75.4B 70.92B 64.61B 122B 8,295B 122B 838B 326B 4,220B 328B 321B 13,992B | P/E 2026 * |
19.4x | P/E 2027 * | 14.6x |
|---|---|---|---|---|---|
| Enterprise Value | 111B 95.36B 89.7B 81.72B 154B 10,491B 154B 1,060B 413B 5,337B 415B 406B 17,696B | EV / Sales 2026 * |
0.56x | EV / Sales 2027 * | 0.55x |
| Free-Float |
99.81% | Yield 2026 * |
1.71% | Yield 2027 * | 1.81% |
Last Transcript : Elevance Health, Inc.
| 1 day | +2.67% | ||
| 1 week | +1.05% | ||
| Current month | +2.67% | ||
| 1 month | +7.24% | ||
| 3 months | +0.09% | ||
| 6 months | +25.95% | ||
| Current year | +14.97% |
| 1 week | 390.8 |  | 404.82 |
| 1 month | 370.47 | | 410.28 |
| Current year | 274.84 | | 436.24 |
| 1 year | 274.84 | | 436.24 |
| 3 years | 273.71 | | 567.26 |
| 5 years | 273.71 | | 567.26 |
| 10 years | 114.85 | | 567.26 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gail Boudreaux
CEO | Chief Executive Officer | 65 | 2017-11-19 |
Mark Kaye
DFI | Director of Finance/CFO | 47 | 2023-10-31 |
Ratnakar Lavu
CTO | Chief Tech/Sci/R&D Officer | 55 | 2024-02-04 |
| Director | Title | Age | Since |
|---|---|---|---|
Ramiro Peru
CHM | Chairman | 70 | - |
Robert Dixon
BRD | Director/Board Member | 70 | 2011-06-30 |
Lewis Hay
BRD | Director/Board Member | 70 | 2013-06-30 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 7/17/26 | Buy | Chairman | 1,000 | 0.0005% | ||
| 7/17/26 | Buy | Chief Executive Officer | 2,725 | 0.0013% | ||
| 5/19/26 | Exercice | Controller/Auditor | 4,593 | 0.0021% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.67% | +1.05% | +26.48% | -8.89% | 87.41B | |
| +1.77% | -0.07% | +27.89% | -16.79% | 356B | |
| +2.53% | +1.34% | -5.92% | +2.31% | 74.8B | |
| +3.04% | +1.33% | +30.04% | -14.27% | 47.42B | |
| +1.38% | +0.35% | +124.62% | +6.46% | 32.22B | |
| +2.16% | +1.72% | +12.29% | -34.59% | 10.58B | |
| +1.42% | 0.00% | -16.93% | +136.35% | 2.82B | |
| +3.61% | +4.12% | +64.12% | +223.31% | 2.28B | |
| +0.27% | -0.62% | +8.41% | -31.34% | 1.97B | |
| Average | +1.72% | +0.38% | +30.11% | +29.17% | 68.36B | |
| Weighted average by Cap. | +1.14% | -0.24% | +28.41% | -10.69% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 196B 169B 159B 145B 273B 18,624B 274B 1,882B 733B 9,474B 737B 721B 31,413B | 200B 173B 163B 148B 279B 19,018B 280B 1,922B 748B 9,674B 752B 736B 32,078B |
| Net income | 4.53B 3.91B 3.68B 3.35B 6.3B 430B 6.33B 43.48B 16.92B 219B 17.02B 16.65B 726B | 5.96B 5.14B 4.84B 4.41B 8.29B 566B 8.33B 57.2B 22.26B 288B 22.39B 21.9B 955B |
| Net Debt | 23.14B 19.96B 18.77B 17.1B 32.16B 2,196B 32.34B 222B 86.38B 1,117B 86.87B 84.98B 3,704B | 21.9B 18.89B 17.77B 16.19B 30.44B 2,078B 30.61B 210B 81.76B 1,057B 82.22B 80.44B 3,506B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-01 | $403.04 | +2.67% | 1,101,998 |
| 26-08-31 | $392.54 | -0.48% | 1,090,737 |
| 26-08-28 | $394.43 | -1.17% | 561,390 |
| 26-08-27 | $399.11 | -0.85% | 569,338 |
| 26-08-26 | $402.54 | +0.92% | 683,861 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ELV Stock
Select your edition
All financial news and data tailored to specific country editions
